Literature DB >> 1977679

Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.

J Bartkova1, D M Barnes, R R Millis, W J Gullick.   

Abstract

The presence of the c-erbB-2 protein, demonstrated immunohistochemically with antibody 21N, has been studied in 72 cases of pure mammary ductal carcinoma in situ. Sixty-one percent of cases showed positive staining. The protein was always present in large-cell comedo type of ductal carcinoma in situ, and never in small-cell cribriform/micropapillary type of ductal carcinoma in situ. When nuclear size was measured, staining was associated with tumors containing cells with large nuclei measuring up to 20 mu, and was never present in lesions containing cells with small nuclei measuring 10 mu or less. In tumors of mixed histopathologic type of ductal carcinoma in situ, variable staining was seen; the cells with small nuclei never stained, while the majority of cells with large nuclei reacted positively. The possible relevance of these findings to the biologic behavior of DCIS is discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977679     DOI: 10.1016/0046-8177(90)90154-w

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  26 in total

1.  Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor.

Authors:  R J Epstein; B J Druker; T M Roberts; C D Stiles
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

Review 2.  Cell polarity in motion: redefining mammary tissue organization through EMT and cell polarity transitions.

Authors:  Nathan J Godde; Ryan C Galea; Imogen A Elsum; Patrick O Humbert
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-12       Impact factor: 2.673

3.  Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ.

Authors:  D M Barnes; J S Meyer; J G Gonzalez; W J Gullick; R R Millis
Journal:  Breast Cancer Res Treat       Date:  1991-03       Impact factor: 4.872

Review 4.  Targeting the HER/EGFR/ErbB family to prevent breast cancer.

Authors:  Louise R Howe; Powel H Brown
Journal:  Cancer Prev Res (Phila)       Date:  2011-08

5.  Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.

Authors:  D N Poller; M Galea; D Pearson; J Bell; W J Gullick; C W Elston; R W Blamey; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

6.  Apocrine adenosis: a precursor of aggressive breast cancer?

Authors:  C A Wells; I L McGregor; C N Makunura; P Yeomans; J D Davies
Journal:  J Clin Pathol       Date:  1995-08       Impact factor: 3.411

Review 7.  The neu-protein and breast cancer.

Authors:  C R De Potter; A M Schelfhout
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

8.  Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma.

Authors:  H Schimmelpenning; E T Eriksson; U G Falkmer; E Azavedo; G Svane; G U Auer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 9.  Biological features of premalignant disease in the human breast.

Authors:  D C Allred; S K Mohsin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

Review 10.  Current management of carcinoma of the breast.

Authors:  T J Eberlein
Journal:  Ann Surg       Date:  1994-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.